CIK 0002007919 · <br>Emerging growth company
Inhibrx Biosciences, Inc.
Sign in to watch- Ticker
- INBX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 990613523
- Phone
- (858) 795-4220
- Business address
- 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
- 4 Open-market buy Chief Executive Officer bought 10,040 shares at an average $84.56 ($848,977)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at an average $99.88 ($998,784)
- 4 Open-market buy Director bought 5,000 shares at $100.00 ($500,000)
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Open-market buy Director bought 5,000 shares at $100.00 ($500,000)
- 4 Open-market sale Director sold 1,500 shares at an average $109.03 ($163,543)
- 4 Open-market sale Director sold 1,000 shares at an average $115.47 ($115,468)
- 4 Open-market buy Director bought 5,000 shares at $113.52 ($567,580)
- 4 Open-market buy Director bought 2,500 shares at $114.65 ($286,617)
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at an average $105.82 ($2,645,399)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 350,000 shares at $32.25 ($11,287,500)
- 4 Derivatives Options or other derivatives
Page 1 of 3 · 59 filings